Sodium inhibits both adenylate cyclase and high-affinity 3H-labeled p-aminoclonidine binding to alpha 2-adrenergic receptors in purified human platelet membranes.
D000067956:Adenylyl Cyclase Inhibitors; D001667:Binding, Competitive; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D002462:Cell Membrane / Q000378:metabolism; D003000:Clonidine / Q000031:analogs & derivatives* / Q000097:blood; D004837:Epinephrine / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D011485:Protein Binding; D011941:Receptors, Adrenergic / Q000378:metabolism*; D011942:Receptors, Adrenergic, alpha / Q000378:metabolism*; D012964:Sodium / Q000494:pharmacology*
D000067956:Adenylyl Cyclase Inhibitors; D011941:Receptors, Adrenergic; D011942:Receptors, Adrenergic, alpha; C016986:apraclonidine; D012964:Sodium; D003000:Clonidine; D004837:Epinephrine